Engagements on the Horizon for Avidity Biosciences
Avidity Biosciences, Inc. (Nasdaq: RNA), a pioneering biopharmaceutical entity, is set to engage with investors in a meaningful way through participation in a series of impactful conferences. The company specializes in Antibody Oligonucleotide Conjugates (AOCs™), which represent a new frontier in RNA therapeutics. This initiative highlights Avidity's commitment to innovation and transparency within the biopharmaceutical space.
Details of the Upcoming Investor Conferences
During these conferences, Avidity's management team will be available to discuss the company’s exciting advances, including their proprietary AOC platform, which merges the precision of oligonucleotide therapies with the specificity of monoclonal antibodies.
Cantor Global Healthcare Conference
Avidity will kick off its conference participation at the Cantor Global Healthcare Conference, scheduled for September 3, 2025. The management will be presenting at 7:20 a.m. PT (10:20 a.m. ET) in New York. This event is pivotal for investors seeking insights into the future of healthcare innovations.
Wells Fargo Healthcare Conference
The following day, Avidity will participate in the 2025 Wells Fargo Healthcare Conference. Scheduled for September 4, 2025, at 9:45 a.m. PT (12:45 p.m. ET), this conference will provide an additional platform for discussions on the company’s pipeline and strategic goals.
Morgan Stanley Global Healthcare Conference
On September 8, 2025, Avidity will conclude its conference series at the Morgan Stanley 23rd Annual Global Healthcare Conference. Presenting at 10:50 a.m. PT (1:50 p.m. ET) in New York, the management will delve into their innovative technologies and the promising results from clinical trials.
Accessing Conference Insights
For investors unable to attend, Avidity will host live webcasts of each event, complete with up-to-date information and archived content. Interested parties can explore the "Events and Presentations" section on Avidity's official website to access these resources, ensuring transparency and ongoing engagement.
About Avidity Biosciences
Avidity Biosciences aims to revolutionize RNA therapies through its Antibody Oligonucleotide Conjugates. The uniqueness of AOC technologies allows for targeted delivery of RNA materials directly into muscle tissues, addressing significant challenges within the space. The current clinical development pipeline includes treatments for rare muscle diseases, including myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy. In addition, Avidity is advancing candidates in precision cardiology for genetic cardiomyopathies.
Moreover, the company is continually growing its pipeline through partnerships that extend the reach of AOCs into cardiology and immunology fields.
Investor Contact Information
For any inquiries, potential investors can reach out to:
Kat Lange
(619) 837-5014
[Contact](mailto:kat@example.com)
Frequently Asked Questions
What is Avidity Biosciences known for?
Avidity Biosciences is known for developing Antibody Oligonucleotide Conjugates (AOCs™) focusing on RNA therapeutic solutions.
What conferences is Avidity participating in?
Avidity will attend the Cantor Global Healthcare Conference, Wells Fargo Healthcare Conference, and Morgan Stanley Global Healthcare Conference.
How does Avidity's AOC technology work?
AOC technology combines monoclonal antibody specificity with oligonucleotide precision to effectively deliver RNA to targeted areas.
Where can I find more information on Avidity's events?
More details can be found on the "Events and Presentations" section of Avidity's official website.
How can I contact Avidity for investor relations?
Investors can contact Kat Lange at (619) 837-5014 for more information.